Acumen Pharmaceuticals, Inc.
ABOSCIK 0001576885 · Biological Products, (No Diagnostic Substances) · Nasdaq
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$116.93M
−18.6% YoY
Q1 May 2026
EPS Diluted (TTM)
−$1.93
−17.0% YoY
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$86.37M
Q1 May 2026
Cash
$51.8M
Q1 May 2026
Total Debt
$31.05M
Q1 May 2026
Shares Outstanding
72.23M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.